Anktiva's Expanded FDA Label Gives ImmunityBio a Larger Market

The Food and Drug Administration has expanded Anktiva's U.S. label to adults with BCG-unresponsive, non-muscle-invasive bladder cancer who have papillary-only tumors. For ImmunityBio, the decision removes a regulatory boundary around a group that was not covered by the drug's original 2024 approval.

Anktiva is used with Bacillus Calmette-Guérin, or BCG, a long-established bladder-cancer therapy. The first approval covered carcinoma in situ, with or without papillary tumors. The new label adds patients whose disease is papillary-only.

A broader label meets a growing commercial base

ImmunityBio said papillary disease accounts for about 85% of non-muscle-invasive bladder-cancer cases, but that percentage is not the same as the number of newly eligible patients. Some patients will not be BCG-unresponsive, and clinical suitability, physician adoption, reimbursement and supply will narrow the addressable population.

The company's recent sales show that Anktiva is already establishing a base. ImmunityBio reported second-quarter product revenue of $50.7 million, up 92% from a year earlier, and first-half product revenue of $94.8 million, up 121%. Those figures predate the expanded label and provide a benchmark for judging whether access to papillary-only patients changes the growth rate.

The approval arrived before the FDA's January 6, 2027 target date. Earlier timing can let commercial teams begin label-based promotion sooner, but it does not guarantee immediate acceleration in prescriptions.

Evidence still matters after approval

The regulatory win does not resolve ImmunityBio's broader risks. The company must supply BCG-linked treatment, secure coverage, convert guideline support into use and fund further clinical programs. Results from QUILT-2.005, which studies Anktiva plus BCG in patients who have not previously received BCG, could address another potential expansion but should not be treated as approved use today.

The stock's muted weekly performance after the announcement shows that investors were weighing more than the label change. Near-term evidence will come from prescription volume, quarterly product revenue, gross margin and management's ability to support broader distribution.

The FDA decision strengthens Anktiva's commercial position because it converts a defined patient group from an off-label opportunity into an approved indication. The size of the benefit will be visible in adoption data, not in the percentage of all bladder tumors alone.